α-MSH at both 10−3 and 10−4 mg/ml significantly reduced TNF-α and IL-1β expression, as compared to the saline- and 10−5 mg/ml α-MSH-treated dry eye corneas and conjunctivas (Fig. 2A,B). Here, IL1B is linked to dry eye syndrome.